Gilead Sciences, Inc. (GILD) operating KPIs
GILDNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026Score 11/30105% above fair value
$170.68+5.07 (+3.06%)
Close on Oct 30, 2026Market cap $211.64BP/E –Yield 1.85%
Gilead Sciences gAAP Research and development (R&D) expenses ($M) ($M)
Form 10-Q / 10-K & Form 8-K
Latest, FY2025
5,799
Period ended Dec 31, 2025
Change on a year earlier
-1.8%
5,907 in FY2024
History
19 years
Since FY2007
Sources
13
Documents cited below
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | GAAP Research and development (R&D) expenses ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 5,799 | -1.8% | Form 10-K (filed 2026-02-24) ↗ |
| FY2024 | Dec 31, 2024 | 5,907 | +3.3% | Form 10-K (filed 2026-02-24) ↗ |
| FY2023 | Dec 31, 2023 | 5,718 | +14.9% | Form 10-K (filed 2026-02-24) ↗ |
| FY2022 | Dec 31, 2022 | 4,977 | +8.2% | Form 10-K (filed 2025-02-28) ↗ |
| FY2021 | Dec 31, 2021 | 4,601 | -6.6% | Form 10-K (filed 2024-02-23) ↗ |
| FY2020 | Dec 31, 2020 | 4,927 | +21.5% | Form 10-K (filed 2023-02-22) ↗ |
| FY2019 | Dec 31, 2019 | 4,055 | +3.4% | Form 10-K (filed 2022-02-23) ↗ |
| FY2018 | Dec 31, 2018 | 3,920 | +5.0% | Form 10-K (filed 2021-02-25) ↗ |
| FY2017 | Dec 31, 2017 | 3,734 | -26.8% | Form 10-K (filed 2019-02-26) ↗ |
| FY2016 | Dec 31, 2016 | 5,098 | +69.1% | Form 10-K (filed 2019-02-26) ↗ |
| FY2015 | Dec 31, 2015 | 3,014 | +5.6% | Form 10-K (filed 2018-02-27) ↗ |
| FY2014 | Dec 31, 2014 | 2,854 | +34.6% | Form 10-K (filed 2017-02-27) ↗ |
| FY2013 | Dec 31, 2013 | 2,120 | +20.5% | Form 10-K (filed 2015-02-25) ↗ |
| FY2012 | Dec 31, 2012 | 1,760 | +43.2% | Form 10-K (filed 2015-02-25) ↗ |
| FY2011 | Dec 31, 2011 | 1,229 | +14.6% | Form 10-K (filed 2012-02-23) ↗ |
| FY2010 | Dec 31, 2010 | 1,073 | +14.2% | Form 10-K (filed 2011-02-28) ↗ |
| FY2009 | Dec 31, 2009 | 940 | +30.2% | Form 10-K (filed 2010-03-01) ↗ |
| FY2008 | Dec 31, 2008 | 722 | +22.1% | Form 10-K (filed 2010-03-01) ↗ |
| FY2007 | Dec 31, 2007 | 591 | – | Form 10-K (filed 2010-03-01) ↗ |
Breakdown
What makes up gaap research and development (r&d) expenses ($m)
Cite this data
StockData. (2026). Gilead Sciences GAAP Research and development (R&D) expenses ($M) ($M), annual FY2007–FY2025 [Data set]. Compiled from Gilead Sciences SEC filings and investor materials. https://stockdatahq.com/stocks/gild/kpis/rd_gaap_tot
See every metric in the Gilead Sciences KPI table. Data updated Oct 29, 2026.